{
    "2020-03-09": [
        [
            {
                "time": "",
                "original_text": "【读财报】血液制品行业首份年报：卫光生物净利润1.7亿元，行业细分市场面临毛利下行压力",
                "features": {
                    "keywords": [
                        "卫光生物",
                        "净利润",
                        "血液制品",
                        "年报",
                        "毛利下行压力"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "血液制品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "卫光生物净利润1.7亿元 行业细分市场面毛利下行压力",
                "features": {
                    "keywords": [
                        "卫光生物",
                        "净利润",
                        "毛利下行压力"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "血液制品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}